Clinical Advances in Hematology & Oncology最新文献

Updates in the management of small cell lung cancer. 小细胞肺癌治疗的最新进展。

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2026-05-01

Jyoti Malhotra

引用次数: 0

How to implement DPYD genotyping into practice. 如何在实践中实施DPYD基因分型。

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2026-05-01

Alan P Venook

引用次数: 0

Hemophagocytic lymphohistiocytosis: new grading classification and targeted therapies. 噬血细胞淋巴组织细胞病：新的分级、分类和靶向治疗。

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2026-05-01

Edo Schaefer, Tishi Shah, Alissa Zhu, Mitchell S Cairo

{"title":"Hemophagocytic lymphohistiocytosis: new grading classification and targeted therapies.","authors":"Edo Schaefer, Tishi Shah, Alissa Zhu, Mitchell S Cairo","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Hemophagocytic lymphohistiocytosis (HLH), both primary/familial HLH and secondary HLH, is associated with multiorgan dysfunction caused by excessive immune activation and cytokine release. The high morbidity and mortality rates are in part due to diagnostic challenges leading to a delay in treatment initiation. The diagnosis, which uses the Histiocyte Society clinical criteria from 2004 and the HScore, remains challenging, with limited improvement in outcomes. No grading system is available for HLH. Although etoposide with dexamethasone remains the most frequently used first-line regimen, various new therapies are now being employed in the management of HLH. The interferon gamma inhibitor emapalumab, the Janus kinase signal transducer and activator of transcription pathway inhibitor ruxolitinib, and the interleukin 6 (IL-6) inhibitor tocilizumab have been trialed in HLH management, with additional treatment options being inhibition of IL-18 and tumor necrosis factor alpha. Here, we summarize current management options for HLH; we also propose a new grading system for HLH based on Common Terminology Criteria for Adverse Events version 5.0 as well as on known prognostic factors (eg, abnormal bilirubin and transaminase levels, elevated creatinine level, respiratory failure, neutropenia, hypertriglyceridemia, hypoalbuminemia, and coagulopathy), which could standardize the diagnosis and guide prompt and appropriate management.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 3","pages":"134-144"},"PeriodicalIF":1.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147845773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Periprocedural management of patients on antithrombotic therapy. 抗栓治疗患者的围手术期管理。

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2026-05-01

Robert D McBane

引用次数: 0

Cabozantinib plus nivolumab as first-line therapy for advanced renal cell carcinoma with bone metastases: a clinical case report. 卡博赞替尼联合纳武单抗作为晚期肾细胞癌骨转移的一线治疗：临床病例报告

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2026-05-01

Daniel J George

引用次数: 0

Update on immune checkpoint inhibition for cervical cancer. 子宫颈癌免疫检查点抑制的最新进展。